|New Treatments for Autoimmune Diseases|
The Institute for Applied Biomedicine has applied for broad patent protection on a drug technology which has considerable promise for the treatment of diseases which are caused by the body's production of undesirable antibodies.
These conditions include many of the autoimmune diseases, such as rheumatoid arthritis, lupus, and several rare autoimmune conditions. Some diseases, such as multiple sclerosis, have deleterious antibodies as only one factor. In these cases, this technology might help to mitigate or partially relieve symptoms.
The principle on which the drug technology is based was established in the scientific literature in 1969. While several treatments were developed and effective in cell cultures, these early formulations were unsafe and never used in humans or animals. With the recent discovery of molecules with extremely specific activity and proven safety, the Institute for Applied Biomedicine was able to modify the original formulations for use in humans.
The Institute has experimental evidence, from its own work and that of other labs and companies, that its immune-modifying drug technology will be both safe and effective. We are developing drugs for several autoimmune conditions, and will proceed with the development of others as soon as funding and internal capacity allow (see Drug Development Plans).
© 1997-2008 Institute for Applied Biomedicine. All Rights Reserved. Legal Notices.